secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-159189
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences raises $180M in private placement (up to $354M with warrants); CEO replaced
--------------------------------------------------------------------------------

- Gross proceeds of $180M upfront; warrants could add $174M if FDA approves cytisinicline for smoking cessation.
- CEO Richard Stewart steps down April 18; remains on board. New CEO Andrew Goldberg appointed.
- Board adds directors Lucian Iancovici and Aaron Royston; Frazier Life Sciences to designate a third.
- Proceeds to fund Phase 3 e-cigarette cessation trial and commercialization of cytisinicline.
- Warrants exercise price $3.51, expire 20 business days after FDA approval announcement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/0001193125-26-159189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-159189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer